Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
354 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Metastatic Pancreatic Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Metastatic Pancreatic Cancer - Pipeline Review, H1 2015', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Metastatic Pancreatic Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Metastatic Pancreatic Cancer - Overview 10 Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 11 Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 12 Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Pancreatic Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Metastatic Pancreatic Cancer - Products under Development by Companies 21 Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 26 Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 27 AbbVie Inc. 27 Aduro BioTech, Inc. 28 AstraZeneca PLC 29 AVEO Pharmaceuticals, Inc. 30 Axcentua Pharmaceuticals AB 31 Bayer AG 32 BioCancell Therapeutics, Inc. 33 Boehringer Ingelheim GmbH 34 Boston Biomedical, Inc. 35 Cantex Pharmaceuticals, Inc. 36 Celgene Corporation 37 Colby Pharmaceutical Company 38 Cornerstone Pharmaceuticals, Inc. 39 Eleison Pharmaceuticals, Inc. 40 Eli Lilly and Company 41 F. Hoffmann-La Roche Ltd. 42 FibroGen, Inc. 43 Fountain Biopharma Inc. 44 Gilead Sciences, Inc. 45 GlaxoSmithKline plc 46 Halozyme Therapeutics, Inc. 47 Immunomedics, Inc. 48 Incyte Corporation 49 Merck & Co., Inc. 50 Merck KGaA 51 Merrimack Pharmaceuticals, Inc. 52 Momenta Pharmaceuticals, Inc. 53 NanoCarrier Co., Ltd. 54 Nanotherapeutics, Inc. 55 NewLink Genetics Corporation 56 Novartis AG 57 Oncolytics Biotech Inc. 58 OncoMed Pharmaceuticals, Inc. 59 Oncovir, Inc. 60 Oncozyme Pharma Inc. 61 Pfizer Inc. 62 Pharma Mar, S.A. 63 Precision Biologics, Inc. 64 Regulon Inc. 65 Rexahn Pharmaceuticals, Inc. 66 Sanofi 67 Silence Therapeutics plc 68 Synta Pharmaceuticals Corp. 69 Takeda Oncology 70 Teva Pharmaceutical Industries Limited 71 Threshold Pharmaceuticals, Inc. 72 Metastatic Pancreatic Cancer - Therapeutics Assessment 73 Assessment by Monotherapy Products 73 Assessment by Combination Products 74 Assessment by Target 75 Assessment by Mechanism of Action 78 Assessment by Route of Administration 81 Assessment by Molecule Type 83 Drug Profiles 85 Atu-027 - Drug Profile 85 AXP-10711 - Drug Profile 87 BBI-608 - Drug Profile 89 BC-819 - Drug Profile 91 bevacizumab - Drug Profile 93 BI-853520 - Drug Profile 98 binimetinib - Drug Profile 100 CEP-37250 - Drug Profile 104 CIM-1 - Drug Profile 105 cisplatin - Drug Profile 106 cisplatin liposomal - Drug Profile 108 clivatuzumab tetraxetan - Drug Profile 110 CPC-410 - Drug Profile 112 CPI-613 - Drug Profile 113 CRS-207 - Drug Profile 115 demcizumab - Drug Profile 117 Dendritic Cell Therapy for Cancer - Drug Profile 121 ensituximab - Drug Profile 122 erismodegib - Drug Profile 124 evofosfamide - Drug Profile 127 FB-704A - Drug Profile 134 FG-3019 - Drug Profile 135 ficlatuzumab - Drug Profile 137 galunisertib - Drug Profile 140 ganetespib - Drug Profile 142 glufosfamide - Drug Profile 146 indoximod - Drug Profile 148 irinotecan sucrosofate liposomal - Drug Profile 150 lapatinib ditosylate - Drug Profile 153 LCL-161 - Drug Profile 157 LGK-974 - Drug Profile 159 lurbinectedin - Drug Profile 160 LY-2109761 - Drug Profile 162 LY-2495655 - Drug Profile 163 MesoCART - Drug Profile 164 MK-2206 - Drug Profile 165 MK-2206 + selumetinib sulfate - Drug Profile 168 MLN-0264 - Drug Profile 170 necuparanib - Drug Profile 171 nimotuzumab - Drug Profile 172 olaparib - Drug Profile 175 paclitaxel albumin bound - Drug Profile 179 paclitaxel lipsomal - Drug Profile 183 PD-0325901 + PF-05212384 - Drug Profile 185 PEGPH-20 - Drug Profile 186 pelareorep - Drug Profile 187 pentamidine isethionate - Drug Profile 192 PGX-100 - Drug Profile 194 pimasertib hydrochloride - Drug Profile 196 plerixafor - Drug Profile 198 Poly-ICLC - Drug Profile 200 PRI-724 - Drug Profile 202 refametinib - Drug Profile 204 rottlerin - Drug Profile 207 ruxolitinib phosphate - Drug Profile 208 RX-0201 - Drug Profile 213 SGT-53 - Drug Profile 215 SiG12D-LODER - Drug Profile 216 simtuzumab - Drug Profile 218 Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile 220 Stem Cell Therapy for Oncology - Drug Profile 221 TL-118 - Drug Profile 222 trametinib dimethyl sulfoxide - Drug Profile 224 Triapine - Drug Profile 227 Vaccine to Target VEGFR-1 and VEGFR-2 for Metastatic Hepatocellular Carcinoma and Metastatic Pancreatic Cancer - Drug Profile 229 veliparib - Drug Profile 230 Metastatic Pancreatic Cancer - Recent Pipeline Updates 233 Metastatic Pancreatic Cancer - Dormant Projects 334 Metastatic Pancreatic Cancer - Discontinued Products 337 Metastatic Pancreatic Cancer - Product Development Milestones 339 Featured News & Press Releases 339 Appendix 348 Methodology 348 Coverage 348 Secondary Research 348 Primary Research 348 Expert Panel Validation 348 Contact Us 349 Disclaimer 349
List of Tables Number of Products under Development for Metastatic Pancreatic Cancer, H1 2015 15 Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2015 16 Number of Products under Development by Companies, H1 2015 18 Number of Products under Development by Companies, H1 2015 (Contd..1) 19 Number of Products under Development by Companies, H1 2015 (Contd..2) 20 Number of Products under Development by Companies, H1 2015 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H1 2015 22 Comparative Analysis by Late Stage Development, H1 2015 23 Comparative Analysis by Clinical Stage Development, H1 2015 24 Comparative Analysis by Early Stage Development, H1 2015 25 Products under Development by Companies, H1 2015 26 Products under Development by Companies, H1 2015 (Contd..1) 27 Products under Development by Companies, H1 2015 (Contd..2) 28 Products under Development by Companies, H1 2015 (Contd..3) 29 Products under Development by Companies, H1 2015 (Contd..4) 30 Products under Investigation by Universities/Institutes, H1 2015 31 Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2015 32 Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H1 2015 33 Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H1 2015 34 Metastatic Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 35 Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2015 36 Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H1 2015 37 Metastatic Pancreatic Cancer - Pipeline by BioCancell Therapeutics, Inc., H1 2015 38 Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 39 Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H1 2015 40 Metastatic Pancreatic Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H1 2015 41 Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2015 42 Metastatic Pancreatic Cancer - Pipeline by Colby Pharmaceutical Company, H1 2015 43 Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 44 Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 45 Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2015 46 Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 47 Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2015 48 Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2015 49 Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H1 2015 50 Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 51 Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2015 52 Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2015 53 Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H1 2015 54 Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H1 2015 55 Metastatic Pancreatic Cancer - Pipeline by Merck KGaA, H1 2015 56 Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 57 Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 58 Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015 59 Metastatic Pancreatic Cancer - Pipeline by Nanotherapeutics, Inc., H1 2015 60 Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H1 2015 61 Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2015 62 Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 63 Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 64 Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2015 65 Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H1 2015 66 Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2015 67 Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2015 68 Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H1 2015 69 Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H1 2015 70 Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 71 Metastatic Pancreatic Cancer - Pipeline by Sanofi, H1 2015 72 Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics plc, H1 2015 73 Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 74 Metastatic Pancreatic Cancer - Pipeline by Takeda Oncology, H1 2015 75 Metastatic Pancreatic Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 76 Metastatic Pancreatic Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 77 Assessment by Monotherapy Products, H1 2015 78 Assessment by Combination Products, H1 2015 79 Number of Products by Stage and Target, H1 2015 81 Number of Products by Stage and Mechanism of Action, H1 2015 84 Number of Products by Stage and Route of Administration, H1 2015 87 Number of Products by Stage and Molecule Type, H1 2015 89 Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2015 238 Metastatic Pancreatic Cancer - Dormant Projects, H1 2015 339 Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H1 2015 340 Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H1 2015 341 Metastatic Pancreatic Cancer - Discontinued Products, H1 2015 342 Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H1 2015 343
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.